Descripción de la empresa
SciSparc Ltd. operates as a clinical-stage pharmaceutical company focused on the development of therapeutics derived from cannabinoid therapies, targeting specific neurological and psychiatric conditions. The enterprise functions within the broader Healthcare sector, specifically the Biotechnology industry, a domain characterized by high research and development expenditures and regulatory scrutiny for new drug approvals. In terms of scale, the company holds a market capitalization of $1.88M and generated total revenue of $1.31M over the trailing twelve months, employing only two individuals to execute its business strategy. These financial metrics indicate that SciSparc Ltd. is a micro-cap entity with minimal operational footprint, suggesting a nascent stage of commercialization where revenue generation is currently limited to early-stage licensing or sales rather than a mature product portfolio. The disparity between the low employee count and the presence of a substantial market cap relative to its revenue implies significant reliance on intellectual property value and external capital rather than operational breadth.
Salud financiera
The company reported revenue of $1.31M for the trailing twelve months, yet it posted a net income of $-6,480,000, revealing a substantial gap where operating expenses vastly outweighed sales proceeds. This negative net income is further evidenced by an EBITDA of $-7,029,000, indicating that the business is burning through cash reserves to fund its drug development programs without generating sufficient operating profitability to cover its costs. While specific figures for free cash flow are not disclosed in the available data, the persistent negative earnings suggest limited financial flexibility and a heavy dependence on external financing to sustain operations. The gross margin stands at 38.7%, which indicates that the cost of goods sold for its cannabinoid-based therapies is controlled enough to retain a significant portion of sales revenue before accounting for overhead. However, the operating margin is severely negative at -569.5%, signaling that administrative, research, and development expenses are exponentially higher than the gross profit generated. Consequently, the profit margin is recorded at 0.0%, reflecting the reality that the company has not yet achieved profitability on a bottom-line basis. Regarding the balance sheet, while cash and debt figures are not available, the debt-to-equity ratio is listed as N/A, which in the context of biotechnology often implies an absence of significant leverage or a capital structure dominated by equity. The current ratio is unavailable, preventing a direct assessment of short-term liquidity relative to current liabilities, though the negative earnings imply potential pressure on working capital. Return on Equity is reported at -1281.5%, a metric that reveals how aggressively the company is leveraging equity capital to pursue growth, while Return on Assets is N/A due to the lack of asset data. These negative return metrics collectively highlight that management is currently incurring losses across the board, a common but risky trajectory for clinical-stage firms attempting to bring complex pharmaceutical products to market.
Evaluación de valoración
SciSparc Ltd. has a trailing P/E ratio of 0.00 and a forward P/E that is not available, a combination that implies the company is currently unprofitable and therefore cannot be valued using traditional earnings-based multiples. The price-to-book ratio is 0.02, indicating that the market values the company's equity at a fraction of its accounting book value, which often occurs in biotech firms where intangible assets like drug candidates are not fully captured on the balance sheet. Additionally, the price-to-sales ratio is 1.44, providing an alternative valuation perspective that prices the firm based on its revenue generation capabilities rather than earnings. The EV/EBITDA multiple is not available, preventing a comparison with peer groups that rely on enterprise value metrics for valuation. In terms of price volatility, the stock has a 52-week high of $94.50 and a 52-week low of $3.30. Assuming the current trading price aligns with the market capitalization of $1.88M against the number of shares outstanding implied by the low price-to-book multiple, the stock is trading significantly below its recent peak, reflecting the high uncertainty surrounding its clinical pipeline. The beta of 1.33 indicates that the stock's price volatility is higher than the broader market, meaning that price movements in SciSparc Ltd. will likely be amplified by market swings. These valuation metrics collectively paint a picture of a high-risk asset priced with a discount relative to its asset base but trading well below its historical high, typical for speculative biotechnology ventures.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which prevents a quantitative analysis of the company's historical growth trajectory or the speed at which earnings are expanding relative to revenue. Given that the company is currently unprofitable with a net loss of $6.48M, it does not pay dividends; consequently, the dividend yield is N/A and the payout ratio is 0.0%. The zero payout ratio confirms that the company retains all available earnings, albeit negative ones, and reinvests any capital inflows directly into its drug development programs for SCI-110 and SCI-210 rather than distributing returns to shareholders. This growth strategy prioritizes the advancement of its clinical-stage assets over immediate income generation for investors. The overall growth and income profile is characterized by a complete absence of current earnings growth and dividend income, relying entirely on future potential from its cannabinoid therapy programs to drive future value creation.